1 Ocak 2014 Dergi makalesi Açık Erişim

Gulcan, Hayrettin Ozan; Unlu, Serdar; Esiringu, Ilker; Ercetin, Tugba; Sahin, Yasemin; Oz, Demet; Sahin, Mustafa Fethi

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/63181</identifier>
  <creators>
    <creator>
      <creatorName>Gulcan, Hayrettin Ozan</creatorName>
      <givenName>Hayrettin Ozan</givenName>
      <familyName>Gulcan</familyName>
    </creator>
    <creator>
      <creatorName>Unlu, Serdar</creatorName>
      <givenName>Serdar</givenName>
      <familyName>Unlu</familyName>
      <affiliation>Nobel Drug Pharmaceut R&amp;D Ctr, TR-81100 Duzce, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Esiringu, Ilker</creatorName>
      <givenName>Ilker</givenName>
      <familyName>Esiringu</familyName>
      <affiliation>Nobel Drug Pharmaceut R&amp;D Ctr, TR-81100 Duzce, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Ercetin, Tugba</creatorName>
      <givenName>Tugba</givenName>
      <familyName>Ercetin</familyName>
      <affiliation>Nobel Drug Pharmaceut R&amp;D Ctr, TR-81100 Duzce, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Sahin, Yasemin</creatorName>
      <givenName>Yasemin</givenName>
      <familyName>Sahin</familyName>
      <affiliation>Nobel Drug Pharmaceut R&amp;D Ctr, TR-81100 Duzce, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Oz, Demet</creatorName>
      <givenName>Demet</givenName>
      <familyName>Oz</familyName>
      <affiliation>Nobel Drug Pharmaceut R&amp;D Ctr, TR-81100 Duzce, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Sahin, Mustafa Fethi</creatorName>
      <givenName>Mustafa Fethi</givenName>
      <familyName>Sahin</familyName>
    </creator>
  </creators>
  <titles>
    <title>Design, Synthesis And Biological Evaluation Of Novel 6H-Benzo[C]Chromen-6-One, And 7,8,9,10-Tetrahydro-Benzo[C]Chromen-6-One Derivatives As Potential Cholinesterase Inhibitors</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2014</publicationYear>
  <dates>
    <date dateType="Issued">2014-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/63181</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.1016/j.bmc.2014.08.016</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Hydroxylated 6H-benzo[c]chromen-6-one derivatives (i.e., urolithins) are the main bioavailable metabolites, and biomarkers of ellagitannins present in various nutrition. Although these dietaries, the sources of urolithins, are employed in folk medicine as cognitive enhancer in the treatment of Alzheimer's Disease, urolithins have negligible potential to inhibit acetylcholinesterase and butyrylcholinesterase enzymes, the validated targets of Alzheimer's Disease. Therefore, within this research, a series of 6H-benzo[c]chromen- 6-one, and 7,8,9,10-tetrahydro-benzo[c]chromen-6-one derivatives has been designed, synthesized, and their biological activities were evaluated as potential acetylcholinesterase and butyrylcholinesterase inhibitors. The compounds synthesized exerted comparable activity in comparison to rivastigmine, galantamine, and donepezil both in in vitro and in vivo studies. (C) 2014 Elsevier Ltd. All rights reserved.</description>
  </descriptions>
</resource>